Chemotherapy-induced peripheral neuropathy is an unseen, but lifelong and potentially debilitating chemotherapy side effect. With very few treatment interventions, prevention and reversal of CIPN has been largely unsuccessful to this point. Clinicians have witnessed patients using off the shelf cryotherapy options, but they are unmeasured, untested, and often ineffective.
Dr Charles Loprizini sits down with oncologists and researchers to discuss what we already know about CIPN’ its impact on physical and psychological quality of life, and why the development of a new cryocompression device is showing real promise in preventing the condition as the next stage of trials begins.
05:57 - What is chemotherapy-induced alopecia?
09:06 - Patient-reported outcomes are needed to assess CIPN
11:39 - Dr Aishwarya Bandla discusses clinical trials looking at cryotherapy for managing CIPN
12:36 - Dr Melissa Accordino explains the pilot study looking at cryocompression at Columbia
13:33 - Dr Raghav Sundar brings us up to speed of the history of using cryotherapy to mitigate CIPN, and the development of the new Paxman Limb Cryocompression System (PLCS)
19:39 - Dr Aishwarya Bandla explains the development of the PLCS in Singapore
21:51 - Patient advocate, Anne Marie Mercurio, discusses the importance of addressing all chemotherapy-induced side effects - as these are cumulative
Dr Charles Loprinzi with Dr Melissa Accordino, Dr Aishwarya Bandla, Dr Stephanie Graff, Anne Marie Mercurio and Dr Raghav Sundar.
Chemotherapy-induced peripheral neuropathy is an unseen, but lifelong and potentially debilitating chemotherapy side effect. With very few treatment interventions, prevention and reversal of CIPN has been largely unsuccessful to this point. Clinicians have witnessed patients using off the shelf cryotherapy options, but they are unmeasured, untested, and often ineffective.
Dr Charles Loprizini sits down with oncologists and researchers to discuss what we already know about CIPN’ its impact on physical and psychological quality of life, and why the development of a new cryocompression device is showing real promise in preventing the condition as the next stage of trials begins.
Chemotherapy-induced peripheral neuropathy is an unseen, but lifelong and potentially debilitating chemotherapy side effect. With very few treatment interventions, prevention and reversal of CIPN has been largely unsuccessful to this point. Clinicians have witnessed patients using off the shelf cryotherapy options, but they are unmeasured, untested, and often ineffective.
Dr Charles Loprizini sits down with oncologists and researchers to discuss what we already know about CIPN’ its impact on physical and psychological quality of life, and why the development of a new cryocompression device is showing real promise in preventing the condition as the next stage of trials begins.
05:57 - What is chemotherapy-induced alopecia?
09:06 - Patient-reported outcomes are needed to assess CIPN
11:39 - Dr Aishwarya Bandla discusses clinical trials looking at cryotherapy for managing CIPN
12:36 - Dr Melissa Accordino explains the pilot study looking at cryocompression at Columbia
13:33 - Dr Raghav Sundar brings us up to speed of the history of using cryotherapy to mitigate CIPN, and the development of the new Paxman Limb Cryocompression System (PLCS)
19:39 - Dr Aishwarya Bandla explains the development of the PLCS in Singapore
21:51 - Patient advocate, Anne Marie Mercurio, discusses the importance of addressing all chemotherapy-induced side effects - as these are cumulative
Dr Charles Loprinzi with Dr Melissa Accordino, Dr Aishwarya Bandla, Dr Stephanie Graff, Anne Marie Mercurio and Dr Raghav Sundar.
